Enhancing vaccine safety capacity globally: A lifecycle perspective

被引：32

作者：

Chen, Robert T. ^{[1
]}

Shimabukuro, Tom T. ^{[1
]}

Martin, David B. ^{[2
]}

Zuber, Patrick L. P. ^{[3
]}

Weibel, Daniel M. ^{[4
]}

Sturkenboom, Miriam ^{[4
]}

机构：

[1] Ctr Dis Control & Prevent, Off Infect Dis, Atlanta, GA USA

[2] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Silver Spring, MD USA

[3] WHO, CH-1211 Geneva, Switzerland

[4] Erasmus Univ, Med Ctr, Rotterdam, Netherlands

来源：

VACCINE | 2015年 / 33卷

关键词：

Vaccine safety; AEFI; Sustainability; Capacity building; LMICs; GUILLAIN-BARRE-SYNDROME; INACTIVATED POLIOVIRUS VACCINATION; REPORTING SYSTEM VAERS; MUMPS-RUBELLA VACCINE; UNITED-STATES; ADVERSE EVENTS; INFLUENZA VACCINE; CUTTER INCIDENT; IMMUNIZATION PRACTICES; CHILDHOOD VACCINATION;

D O I：

10.1016/j.vaccine.2015.06.073

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Major vaccine safety controversies have arisen in several countries beginning in the last decades of 20th century. Such periodic vaccine safety controversies are unlikely to go away in the near future as more national immunization programs mature with near elimination of target vaccine-preventable diseases that result in relative greater prominence of adverse events following immunizations, both true reactions and temporally coincidental events. There are several ways in which vaccine safety capacity can be improved to potentially mitigate the impact of future vaccine safety controversies. This paper aims to take a "lifecycle" approach, examining some potential pre- and post-licensure opportunities to improve vaccine safety, in both developed (specifically U.S. and Europe) and low- and middle-income countries. (C) 2015 by American Journal of Preventive Medicine and Elsevier Ltd. All rights reserved.

引用

页码：D46 / D54

页数：9

共 152 条

[11]

[Anonymous], 2011, MEDICINE, DOI DOI 10.17226/13164

[12]

[Anonymous], VACCINE

[13] The Vaccine Safety Datalink: A Model for Monitoring Immunization Safety [J].

Baggs, James ;

Gee, Julianne ;

Lewis, Edwin ;

Fowler, Gabrielle ;

Benson, Patti ;

Lieu, Tracy ;

Naleway, Allison ;

Klein, Nicola P. ;

Baxter, Roger ;

Belongia, Edward ;

Glanz, Jason ;

Hambidge, Simon J. ;

Jacobsen, Steven J. ;

Jackson, Lisa ;

Nordin, Jim ;

Weintraub, Eric .

PEDIATRICS, 2011, 127 :S45-S53

[14]

Baker MKD, 2013, ADULT PEDIAT VACCINE

[15] Hepatitis B vaccination and French Society ten years after the suspension of the vaccination campaign: How should we raise infant immunization coverage rates? [J].

Balinska, Marta A. .

JOURNAL OF CLINICAL VIROLOGY, 2009, 46 (03) :202-205

[16] Risky business: Challenges in vaccine risk communication [J].

Ball, LK ;

Evans, G ;

Bostrom, A .

PEDIATRICS, 1998, 101 (03) :453-458

[17] HLA Type and Immune Response to Borrelia burgdorferi Outer Surface Protein A in People in Whom Arthritis Developed After Lyme Disease Vaccination [J].

Ball, Robert ;

Shadomy, Sean V. ;

Meyer, Abbie ;

Huber, Brigitte T. ;

Leffell, Mary S. ;

Zachary, Andrea ;

Belotto, Michael ;

Hilton, Eileen ;

Bryant-Genevier, Marthe ;

Schriefer, Martin E. ;

Miller, Frederick W. ;

Braun, M. Miles .

ARTHRITIS AND RHEUMATISM, 2009, 60 (04) :1179-1186

[18] Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action [J].

Barker, Charlotte I. S. ;

Snape, Matthew D. .

LANCET INFECTIOUS DISEASES, 2014, 14 (03) :227-238

[19] Pertussis vaccine encephalopathy: 'Oh! Let us never, never doubt ... [J].

Baxter, Peter .

DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2010, 52 (10) :883-884

[20]

Baylor NW., 2012, VACCINES EXPERT CONS, V6th, P1427

← 1 2 3 4 5 6 7 8 9 10 →